Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT

Launched by YI ZHANG · Jan 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a traditional treatment called moxibustion might help prevent a condition known as hemorrhagic cystitis in patients receiving a type of stem cell transplant called allogeneic hematopoietic stem cell transplantation (allo-HSCT). Hemorrhagic cystitis is when the bladder becomes inflamed and can bleed, which can happen after the transplant. In the trial, participants will be divided into two groups: one will receive standard care, and the other will receive moxibustion treatments for two weeks starting right after their transplant. Researchers will monitor various health indicators, including urine tests and virus levels, to see if moxibustion helps reduce the risk of developing this condition.

To be eligible for this trial, patients should be between 18 and 55 years old, have certain blood diseases, and be willing to participate by signing an informed consent form. It’s important to note that individuals with skin issues at the treatment sites or those who have had specific types of prior treatments may not qualify. Participants can expect to receive care at multiple centers and will undergo regular health checks during the study. This research aims to find out if adding moxibustion to standard care can improve outcomes for patients undergoing this critical treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF);
• • 2. Age: 14-60 years;
• • 3. Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT;
• Exclusion Criteria:
• • 1. refuse to participate in this clinical study;
• • 2. The corresponding skin at the moxibustion site is broken or sensitive;
• • 3. allo-HSCT pretreated with the RIC program;